ArticleDer Urologe. Ausg. A2007
[The value of imaging techniques for bone metastases].
Article in Der Urologe. Ausg. A, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone metastases are common by prostate and renal carcinomas but prostate carcinomas are predominantly osteoblastic metastases and renal carcinomas often osteolytic. Apart from bone scintigraphy and conventional X-ray imaging, computed tomography (CT), magnetic resonance tomography (MRT) and positron emission tomography (PET) can also be used for primary diagnosis. X-rays and CT are less sensitive but better for evaluating the stability of metastases. Primary diagnosis of prostate carcinomas should encompass selective bone imaging and skeletal scintigraphy is also recommended. Local recurrences or lymph node metastases can be detected using PET with (11)C-choline. MRT is the method with higher sensitivity and specificity but for whole body scans is, at present, very time-consuming and, therefore, impractical and cost-intensive. However, for selective, non-invasive valency evaluation of suspect metastases, it is considered the gold standard for the tumor entities prostate and renal carcinomas where the results of FDG PET are consistently negative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.